BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

PreciseDx® announced that its analytical validation study for its PreciseBreast™ assessment has been published in the November 3, 2023 issue of Clinical Breast Cancer.

Turn Biotechnologies, a cell rejuvenation developer of novel mRNA medicines for untreatable, age-related conditions, announced it is the first company to safely and specifically deliver mRNA in vivo in the skin without any off-target organ uptake.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, announced that a UK-based global full-service contract research organization, selected ValGenesis VLMS to digitize its corporate validation process.

Crown Bioscience announced the launch of its ground-breaking service offering, OrganoidXploreTM.

Moleculin Biotech, Inc. , today announced that it will report its financial results for the third quarter ended September 30, 2023 , on Monday November 13, 2023. Moleculin management will host a conference call and live webcast to discuss the operational and financial results at 8:30 AM ET that same day.

Royal Philips, a global leader in health technology, announced it has received a second round of funding from the Bill & Melinda Gates Foundation to accelerate global adoption of AI algorithms on Philips Lumify Handheld Ultrasound.

Alpha Pro Tech, Ltd. announced financial results for the three and nine month period ended September 30, 2023.

Capricor Therapeutics will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 14, 2022 at 8:30 AM GMT (3:30 AM Eastern Time).